Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7680) 7680
Newspaper Article (457) 457
Book Chapter (40) 40
Magazine Article (31) 31
Newsletter (24) 24
Book / eBook (7) 7
Trade Publication Article (5) 5
Publication (4) 4
Reference (4) 4
Transcript (4) 4
Web Resource (3) 3
Conference Proceeding (2) 2
Report (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (6514) 6514
humans (6390) 6390
life sciences & biomedicine (6241) 6241
oncology (3427) 3427
male (2891) 2891
female (2888) 2888
middle aged (2206) 2206
imatinib mesylate (1962) 1962
adult (1959) 1959
antineoplastic agents - administration & dosage (1905) 1905
cancer (1807) 1807
aged (1757) 1757
animals (1636) 1636
hematology (1635) 1635
pyrimidines - administration & dosage (1587) 1587
benzamides (1565) 1565
treatment outcome (1542) 1542
biological and medical sciences (1539) 1539
medical sciences (1510) 1510
dose-response relationship, drug (1428) 1428
drug dosages (1414) 1414
tumors (1401) 1401
piperazines - administration & dosage (1332) 1332
research (1325) 1325
pharmacology & pharmacy (1296) 1296
chemotherapy (1291) 1291
care and treatment (1282) 1282
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1223) 1223
antineoplastic agents (1206) 1206
antineoplastic agents - therapeutic use (1159) 1159
dosage and administration (1126) 1126
drug therapy (1110) 1110
leukemia (1099) 1099
antineoplastic combined chemotherapy protocols - therapeutic use (947) 947
protein kinase inhibitors - administration & dosage (944) 944
chronic myeloid leukemia (926) 926
imatinib (887) 887
cell line, tumor (829) 829
medicine & public health (812) 812
mice (808) 808
antimitotic agents (804) 804
cancer therapies (793) 793
antineoplastic agents - adverse effects (792) 792
pyrimidines - therapeutic use (788) 788
patients (781) 781
kinases (774) 774
health aspects (761) 761
analysis (749) 749
clinical trials (717) 717
antineoplastic agents - pharmacology (712) 712
mutation (705) 705
protein kinase inhibitors - therapeutic use (685) 685
aged, 80 and over (666) 666
neoplasms - drug therapy (665) 665
piperazines - therapeutic use (652) 652
apoptosis (635) 635
adolescent (630) 630
hematologic and hematopoietic diseases (622) 622
pharmacology. drug treatments (608) 608
abridged index medicus (586) 586
tyrosine (580) 580
young adult (557) 557
metastasis (548) 548
pyrimidines - adverse effects (547) 547
leukemias. malignant lymphomas. malignant reticulosis. myelofibrosis (545) 545
cell proliferation - drug effects (537) 537
apoptosis - drug effects (535) 535
proteins (532) 532
pyrimidines - pharmacology (530) 530
disease-free survival (529) 529
studies (512) 512
prognosis (495) 495
dasatinib (489) 489
hemic and lymphatic diseases (483) 483
protein kinase inhibitors - pharmacology (473) 473
protein-tyrosine kinases - antagonists & inhibitors (472) 472
drug administration schedule (471) 471
hematology, oncology and palliative medicine (450) 450
time factors (449) 449
protein kinase inhibitors - adverse effects (443) 443
drug resistance, neoplasm (441) 441
genetic aspects (438) 438
medicine (438) 438
risk factors (438) 438
leukemia, myelogenous, chronic, bcr-abl positive - genetics (432) 432
complications and side effects (422) 422
piperazines - pharmacology (418) 418
piperazines - adverse effects (414) 414
retrospective studies (414) 414
pharmacology/toxicology (408) 408
leukemia, myelogenous, chronic, bcr-abl positive - pathology (403) 403
research article (394) 394
medical research (392) 392
follow-up studies (387) 387
administration, oral (385) 385
fusion proteins, bcr-abl - genetics (379) 379
drug resistance (376) 376
drugs (376) 376
signal transduction - drug effects (375) 375
antineoplastic combined chemotherapy protocols - administration & dosage (373) 373
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8174) 8174
German (44) 44
Japanese (33) 33
French (30) 30
Russian (22) 22
Chinese (11) 11
Spanish (8) 8
Polish (7) 7
Portuguese (7) 7
Hungarian (6) 6
Italian (4) 4
Danish (3) 3
Dutch (3) 3
Swedish (2) 2
Turkish (2) 2
Czech (1) 1
Korean (1) 1
Norwegian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial
by Joensuu, Heikki and Eriksson, Mikael and Sundby Hall, Kirsten and Hartmann, Jörg T and Pink, Daniel and Schütte, Jochen and Ramadori, Giuliano and Hohenberger, Peter and Duyster, Justus and Al-Batran, Salah-Eddin and Schlemmer, Marcus and Bauer, Sebastian and Wardelmann, Eva and Sarlomo-Rikala, Maarit and Nilsson, Bengt and Sihto, Harri and Monge, Odd R and Bono, Petri and Kallio, Raija and Vehtari, Aki and Leinonen, Mika and Alvegård, Thor and Reichardt, Peter
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2012, Volume 307, Issue 12, pp. 1265 - 1272
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Biological and medical sciences | General aspects | Medical sciences | Tumors | Piperazines - administration & dosage | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Chemotherapy, Adjuvant | Gastrointestinal Stromal Tumors - genetics | Gastrointestinal Stromal Tumors - surgery | Drug Administration Schedule | Neoplasm Recurrence, Local - prevention & control | Pyrimidines - administration & dosage | Gastrointestinal Neoplasms - surgery | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Receptor, Platelet-Derived Growth Factor alpha - genetics | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Clinical trials | Postoperative period | Drug therapy | Digestive system | Pathology | tumors | Hospitals | Reviews | Safety engineering | survival | Mutation | intervention | surgery | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
by Mahon, François-Xavier, Prof and Réa, Delphine, MD and Guilhot, Joëlle, PhD and Guilhot, François, Prof and Huguet, Françoise, MD and Nicolini, Franck, MD and Legros, Laurence, MD and Charbonnier, Aude, MD and Guerci, Agnès, MD and Varet, Bruno, Prof and Etienne, Gabriel, MD and Reiffers, Josy, Prof and Rousselot, Philippe, Prof and on behalf of the Intergroupe Français des Leucémies Myéloïdes Chroniques (FILMC) and FILMC and Intergroupe Français des Leucémies Myéloïdes Chroniques
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Recurrence | Prospective Studies | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Time Factors | Aged, 80 and over | Adult | Female | France | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Benzamides | Antimitotic agents | Arson | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
by Saglio, Giuseppe and Hochhaus, Andreas and Goh, Yeow Tee and Masszi, Tamas and Pasquini, Ricardo and Maloisel, Frederic and Erben, Philipp and Cortes, Jorge and Paquette, Ronald and Bradley-Garelik, M. Brigid and Zhu, Chao and Dombret, Herve
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 16, pp. 3852 - 3861
Dasatinib | Imatinib | Blast crisis | Chronic myeloid leukemia | Drug resistance | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Thiazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Thiazoles - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Adolescent | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Aged | Benzamides | Blast Crisis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Care and treatment | Patient outcomes | Dosage and administration | Research | Index Medicus | Abridged Index Medicus | imatinib | chronic myeloid leukemia | dasatinib | drug resistance | blast crisis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
by Kirk R. Schultz and W. Paul Bowman and Alexander Aledo and William B. Slayton and Harland Sather and Meenakshi Devidas and Chenguang Wang and Stella M. Davies and Paul S. Gaynon and Michael Trigg and Robert Rutledge and Laura Burden and Dean Jorstad and Andrew Carroll and Nyla A. Heerema and Naomi Winick and Michael J. Borowitz and Stephen P. Hunger and William L. Carroll and Bruce Camitta
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 31, pp. 5175 - 5181
Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Child, Preschool | Infant | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Bone Marrow Transplantation | Adult | Female | Child | Philadelphia Chromosome | Pyrimidines - administration & dosage | Risk Factors | Kaplan-Meier Estimate | Imatinib Mesylate | Piperazines - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Adolescent | Pyrimidines - adverse effects | Benzamides | Index Medicus | Original Reports | Hema5 | Bios3 | Pedi2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: Two-year follow-up of a randomized phase 2 study (START-R)
by Kantarjian, Hagop and Pasquini, Ricardo and Lévy, Vincent and Jootar, Saengsuree and Holowiecki, Jerzy and Hamerschlak, Nelson and Hughes, Timothy and Bleickardt, Eric and Dejardin, David and Cortes, Jorge and Shah, Neil P
Cancer, ISSN 0008-543X, 09/2009, Volume 115, Issue 18, pp. 4136 - 4147
Dasatinib | Imatinib | Chronic myeloid leukemia | Drug resistance | Life Sciences & Biomedicine | Oncology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Tumors | Piperazines - administration & dosage | Drug Administration Schedule | Follow-Up Studies | Pyrimidines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - drug therapy | Middle Aged | Drug Resistance, Neoplasm | Thiazoles - therapeutic use | Withholding Treatment | Imatinib Mesylate | Piperazines - adverse effects | Thiazoles - adverse effects | Cross-Over Studies | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged, 80 and over | Adult | Female | Aged | Benzamides | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus | imatinib | chronic myeloid leukemia | dasatinib | drug resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial
by Kang, Yoon-Koo, Prof and Ryu, Min-Hee, MD and Yoo, Changhoon, MD and Ryoo, Baek-Yeol, Prof and Kim, Hyun Jin, MD and Lee, Jong Jin, MD and Nam, Byung-Ho, PhD and Ramaiya, Nikhil, MBBS and Jagannathan, Jyothi, MD and Demetri, George D, Prof
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1175 - 1182
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastrointestinal Stromal Tumors - enzymology | Piperazines - administration & dosage | Prospective Studies | Gastrointestinal Stromal Tumors - secondary | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Indoles - administration & dosage | Benzamides - administration & dosage | Time Factors | Antineoplastic Agents - adverse effects | Pyrroles - administration & dosage | Pyrroles - adverse effects | Female | Gastrointestinal Stromal Tumors - mortality | Benzamides - adverse effects | Republic of Korea | Double-Blind Method | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Gastrointestinal Stromal Tumors - drug therapy | Pyrimidines - adverse effects | Aged | Antimitotic agents | Clinical trials | Product development | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
by Talpaz, Moshe and Shah, Neil P and Kantarjian, Hagop and Donato, Nicholas and Nicoll, John and Paquette, Ron and Cortes, Jorge and O'Brien, Susan and Nicaise, Claude and Bleickardt, Eric and Blackwood-Chirchir, M. Anne and Iyer, Vishwanath and Chen, Tai-Tsang and Huang, Fei and Decillis, Arthur P and Sawyers, Charles L
The New England journal of medicine, ISSN 0028-4793, 06/2006, Volume 354, Issue 24, pp. 2531 - 2541
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Thiazoles - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Neutropenia - chemically induced | Dasatinib | Piperazines | Pyrimidines - administration & dosage | Genotype | Imatinib Mesylate | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Drugs | Product/Service Evaluations | Chronic myeloid leukemia | Drug therapy | Bone marrow | Kinases | Leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity
by White, Deborah L and Saunders, Verity A and Dang, Phuong and Engler, Jane and Venables, Amity and Zrim, Stephanie and Zannettino, Andrew and Lynch, Kevin and Manley, Paul W and Hughes, Timothy
Blood, ISSN 0006-4971, 12/2007, Volume 110, Issue 12, pp. 4064 - 4072
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Protein Kinase Inhibitors - pharmacokinetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - blood | Humans | Risk Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Organic Cation Transporter 1 - metabolism | Imatinib Mesylate | Remission Induction | Dose-Response Relationship, Drug | Time Factors | Pyrimidines - pharmacokinetics | Adult | Female | Benzamides | Piperazines - pharmacokinetics | Cohort Studies | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
by Schöffski, P and Reichardt, P and Blay, J.-Y and Dumez, H and Morgan, J.A and Ray-Coquard, I and Hollaender, N and Jappe, A and Demetri, G.D
Annals of oncology, ISSN 0923-7534, 10/2010, Volume 21, Issue 10, pp. 1990 - 1998
gastrointestinal stromal tumors | imatinib | GIST | everolimus (RAD001) | Everolimus (RAD001) | Gastrointestinal stromal tumors | Imatinib | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Stomach. Duodenum. Small intestine. Colon. Rectum. Anus | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Piperazines - administration & dosage | Sirolimus - analogs & derivatives | Pyrimidines - administration & dosage | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Survival Rate | Treatment Outcome | Imatinib Mesylate | Neoplasm Recurrence, Local - pathology | Sirolimus - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Gastrointestinal Stromal Tumors - drug therapy | Gastrointestinal Stromal Tumors - pathology | Aged, 80 and over | Adult | Female | Aged | Benzamides | Neoplasm Staging | Everolimus | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
by Saglio, Giuseppe and Kim, Dong-Wook and Issaragrisil, Surapol and le Coutre, Philipp and Etienne, Gabriel and Lobo, Clarisse and Pasquini, Ricardo and Clark, Richard E and Hochhaus, Andreas and Hughes, Timothy P and Gallagher, Neil and Hoenekopp, Albert and Dong, Mei and Haque, Ariful and Larson, Richard A and Kantarjian, Hagop M and ENESTnd Investigators and Sahlgrenska akademin and Göteborgs universitet and Institutionen för medicin, avdelningen för invärtesmedicin and Gothenburg University and Institute of Medicine, Department of Internal Medicine and Sahlgrenska Academy
The New England journal of medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2251 - 2259
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Blast Crisis - prevention & control | Protein Kinase Inhibitors - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Kaplan-Meier Estimate | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Benzamides | Nilotinib | Antiviral agents | Safety and security measures | Chronic myeloid leukemia | Drug therapy | Comparative analysis | Clinical trials | Drug dosages | Medical treatment | Index Medicus | Abridged Index Medicus | bcr-abl | pathology | Leukemia | Chronic-Phase | Myeloid | Klinisk medicin | 80 and over | Pyrimidines | administration & dosage | Fusion Proteins | Blast Crisis | drug therapy | Piperazines | Antineoplastic Agents | prevention & control | antagonists & inhibitors | Clinical Medicine | Protein Kinase Inhibitors | adverse effects | therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights